New shot aims to stop repeat heart sac inflammation

NCT ID NCT07010159

Recruiting now Disease control Sponsor: Kiniksa Pharmaceuticals International, plc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests an injected drug called KPL-387 in 165 people with recurrent pericarditis, a condition where the sac around the heart becomes inflamed again and again. The goal is to see if KPL-387 can reduce flare-ups and pain better than a placebo. Participants must have symptoms despite standard treatments like NSAIDs or colchicine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KPL-387 (injected under the skin)
What this could lead to: If successful, this could provide a new treatment option to control recurrent pericarditis and reduce painful flare-ups.
What could go wrong: This is an early-to-mid stage trial with only 165 participants. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic recurrent pericarditis pericarditis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PERICARDITIS PERICARDITIS ACUTE RECURRENT PERICARDITIS

Contacts and locations

Locations

Investigational Site 001
WITHDRAWN

Columbus, Georgia, 31904, United States
Investigational Site 002
WITHDRAWN

Overland Park, Kansas, 66221, United States
Investigational Site 003
RECRUITING

Cleveland, Ohio, 44195, United States
Investigational Site 004
RECRUITING

Chicago, Illinois, 60611, United States
Investigational Site 005
RECRUITING

Austin, Texas, 78705, United States
Investigational Site 006
RECRUITING

Charlottesville, Virginia, 22903, United States
Investigational Site 007
RECRUITING

Milan, 20157, Italy
Investigational Site 008
RECRUITING

San Francisco, California, 94158, United States
Investigational Site 009
RECRUITING

Cincinnati, Ohio, 45219, United States
Investigational Site 010
RECRUITING

Barcelona, 8035, Spain
Investigational Site 011
RECRUITING

Murcia, 30120, Spain
Investigational Site 012
RECRUITING

Rochester, Minnesota, 55905, United States
Investigational Site 013
RECRUITING

Houston, Texas, 77030, United States
Investigational Site 014
RECRUITING

Indianapolis, Indiana, 46184, United States
Investigational Site 015
RECRUITING

New York, New York, 10016, United States
Investigational Site 016
RECRUITING

Westminster, Colorado, 80023, United States
Investigational Site 017
RECRUITING

Southampton, SO17 1BJ, United Kingdom
Investigational Site 018
RECRUITING

Gilbert, Arizona, 85297, United States
Investigational Site 019
RECRUITING

Poitiers, 86000, France
Investigational Site 020
RECRUITING

London, EC1A 7BE, United Kingdom
Investigational Site 021
RECRUITING

Paris, 75013, France
Investigational Site 022
RECRUITING

New York, New York, 10032, United States
Investigational Site 023
RECRUITING

Norfolk, Virginia, 23507, United States
Investigational Site 024
RECRUITING

Madrid, 28850, Spain
Investigational Site 025
RECRUITING

Belgrade, 11000, Serbia
Investigational Site 026
RECRUITING

Belgrade, 11040, Serbia
Investigational Site 027
RECRUITING

Ottawa, Ontario, K1N 6N5, Canada
Investigational Site 028
RECRUITING

Montpellier, 34090, France
Investigational Site 029
RECRUITING

Genoa, 16132, Italy
Investigational Site 030
RECRUITING

Los Angeles, California, 90048, United States
Investigational Site 031
RECRUITING

Warsaw, 02-507, Poland
Investigational Site 032
RECRUITING

Voula, 166 73, Greece
Investigational Site 033
RECRUITING

Udine, 33100, Italy
Investigational Site 034
RECRUITING

Athens, 115 28, Greece
Investigational Site 035
RECRUITING

London, SE1 7EH, United Kingdom
Investigational Site 036
RECRUITING

Pessac, 33600, France
Investigational Site 037
RECRUITING

Toulouse, 31400, France
Investigational Site 038
RECRUITING

Toulouse, 31400, France
Investigational Site 039
RECRUITING

Nea Ionia, 142 33, Greece
Investigational Site 040
RECRUITING

Genoa, 16147, Italy
Investigational Site 041
RECRUITING

Varese, 21100, Italy
Investigational Site 042
RECRUITING

Burlington, Vermont, 05401, United States
Investigational Site 043
RECRUITING

Baltimore, Maryland, 21287, United States
Investigational Site 044
RECRUITING

Santa Monica, California, 90404, United States
Investigational Site 045
RECRUITING

Richmond, Virginia, 23284, United States
Investigational Site 046
RECRUITING

Kansas City, Missouri, 66160, United States
Investigational Site 047
RECRUITING

London, NW3 2QG, United Kingdom
Investigational Site 048
RECRUITING

Barcelona, 08017, Spain
Investigational Site 050
RECRUITING

Kansas City, Missouri, 64111, United States
Investigational Site 050
RECRUITING

Padua, 35143, Italy
Investigational Site 051
RECRUITING

Warsaw, 02-097, Poland
Investigational Site 052
RECRUITING

Dresden, 01069, Germany
Investigational Site 053
RECRUITING

Phoenix, Arizona, 85054, United States
Investigational Site 054
RECRUITING

Boston, Massachusetts, 02411, United States
Investigational Site 055
RECRUITING

Minneapolis, Minnesota, 55407, United States
Investigational Site 056
RECRUITING

Milan, 20132, Italy
Investigational Site 057
RECRUITING

Valencia, 46015, Spain
Investigational Site 058
RECRUITING

Ventura, California, 93003, United States
Investigational Site 059
RECRUITING

Turin, 10126, Italy
Investigational Site 060
RECRUITING

Florence, 50134, Italy
Investigational Site 061
RECRUITING

Washington D.C., District of Columbia, 20010, United States
Investigational Site 062
RECRUITING

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.